Literature DB >> 25989816

Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease.

G Samonis1, K Z Vardakas2, G S Tansarli2, D Dimopoulou1, G Papadimitriou1, D P Kofteridis1, S Maraki3, M Karanika4, M E Falagas2.   

Abstract

We studied the epidemiology and microbiology of Clostridium difficile and the characteristics of patients with C. difficile infection (CDI) in Crete in three groups of hospitalized patients with diarrhoea: group 1 [positive culture and positive toxin by enzyme immunoassay (EIA)]; group 2 (positive culture, negative toxin); group 3 (negative culture, negative toxin). Patients in group 1 were designated as those with definitive CDI (20 patients for whom data was available) and matched with cases in group 2 (40 patients) and group 3 (40 patients). C. difficile grew from 6% (263/4379) of stool specimens; 14·4% of these had positive EIA, of which 3% were resistant to metronidazole. Three isolates had decreased vancomycin susceptibility. Patients in groups 1 and 2 received more antibiotics (P = 0·03) and had more infectious episodes (P = 0·03) than patients in group 3 prior to diarrhoea. Antibiotic administration for C. difficile did not differ between groups 1 and 2. Mortality was similar in all three groups (10%, 12·5% and 5%, P = 0·49). CDI frequency was low in the University Hospital of Crete and isolates were susceptible to metronidazole and vancomycin.

Entities:  

Keywords:  C. difficile mortality; C. difficile resistance; C. difficile susceptibility; C. difficile toxin; C. difficile-associated diarrhoea

Mesh:

Substances:

Year:  2015        PMID: 25989816      PMCID: PMC9507283          DOI: 10.1017/S0950268815000837

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  43 in total

1.  Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics.

Authors:  Marjolein P M Hensgens; Abraham Goorhuis; Olaf M Dekkers; Ed J Kuijper
Journal:  J Antimicrob Chemother       Date:  2011-12-06       Impact factor: 5.790

2.  Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.

Authors:  Sailajah Janarthanan; Ivo Ditah; Douglas G Adler; Murray N Ehrinpreis
Journal:  Am J Gastroenterol       Date:  2012-06-19       Impact factor: 10.864

3.  Hospital Clostridium difficile infection testing rates: is "don't ask, don't tell" at play?

Authors:  Kevin A Brown; David N Fisman; Nick Daneman
Journal:  Infect Control Hosp Epidemiol       Date:  2014-07       Impact factor: 3.254

4.  Characterization and antimicrobial susceptibility of Clostridium difficile strains isolated from adult patients with diarrhoea hospitalized in two university hospitals in Poland, 2004-2006.

Authors:  Hanna Pituch; Piotr Obuch-Woszczatyński; Dorota Wultańska; Grażyna Nurzyńska; Celine Harmanus; Aleksandra Banaszkiewicz; Andrzej Radzikowski; Mirosław Łuczak; Alex van Belkum; Ed Kuijper
Journal:  J Med Microbiol       Date:  2011-03-17       Impact factor: 2.472

5.  A prospective study of community-associated Clostridium difficile infections: the role of antibiotics and co-infections.

Authors:  Surabhi K Taori; Allison Wroe; Alison Hardie; Alan P Gibb; Ian R Poxton
Journal:  J Infect       Date:  2014-04-26       Impact factor: 6.072

6.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

7.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study.

Authors:  Herman Goossens; Matus Ferech; Robert Vander Stichele; Monique Elseviers
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

8.  Outcomes in patients tested for Clostridium difficile toxins.

Authors:  Christopher R Polage; David L Chin; Jhansi L Leslie; Jevon Tang; Stuart H Cohen; Jay V Solnick
Journal:  Diagn Microbiol Infect Dis       Date:  2012-09-23       Impact factor: 2.803

9.  Does the handling time of unrefrigerated human fecal specimens impact the detection of Clostridium difficile toxins in a hospital setting?

Authors:  Chintan Modi; Joseph R DePasquale; Nhat Q Nguyen; Judith E Malinowski; George Perez
Journal:  Indian J Gastroenterol       Date:  2010-08-26

Review 10.  Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis.

Authors:  Konstantinos Z Vardakas; Athanasios A Konstantelias; Giorgos Loizidis; Petros I Rafailidis; Matthew E Falagas
Journal:  Int J Infect Dis       Date:  2012-08-22       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.